Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Small molecule chaperones (SMCs)"'
Autor:
Isabel Cardoso, Márcia A. Liz, Ana Gimeno, Josep Rivas, Ellen Y. Cotrina, Gemma Arsequell, Jordi Llop, Jesús Jiménez-Barbero, José P. Leite, Daniel Blasi, Luis Miguel Santos, Luís Gales, Maria Antònia Busquets, Antoni Planas, Rafel Prohens, Jordi Quintana
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
Transthyretin (TTR) has a well-established role in neuroprotection in Alzheimer's Disease (AD). We have setup a drug discovery program of small-molecule compounds that act as chaperones enhancing TTR/Amyloid-beta peptide (Aβ) interactions. A combina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1030e2b5b44fae8a2166ca6577285669
https://pubmed.ncbi.nlm.nih.gov/34555615
https://pubmed.ncbi.nlm.nih.gov/34555615
Autor:
Rafel Prohens, Jordi Quintana, Ellen Y. Cotrina, Gregorio Valencia, Jesús Jiménez-Barbero, Ana Gimeno, Isabel Cardoso, Jordi Llop, Gemma Arsequell
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal of Medicinal Chemistry
instname
Journal of Medicinal Chemistry
The plasma protein transthyretin (TTR) modulates Abeta (Aβ) peptides deposition, processing and toxicity. We have shown that this physiological effect is enhanced in mice by treatment with compounds such as iododiflunisal (IDIF) which is a good TTR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9e26892adf4a6d0311ffad0f02df93c
http://hdl.handle.net/10261/233259
http://hdl.handle.net/10261/233259
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Bazazzadegan, Niloofar1, Shasaltaneh, Marzieh Dehghan2, Saliminejad, Kioomars3, Kamali, Koorosh3, Banan, Mehdi1, Nazari, Reza2, Riazi, Gholam Hossein2, Khorram Khorshid, Hamid Reza1 hrkk1@uswr.ac.ir
Publikováno v:
Advanced Pharmaceutical Bulletin. 2017, Vol. 7 Issue 4, p629-636. 8p.
Publikováno v:
FEBS Letters; Aug2005, Vol. 579 Issue 21, p4775-4780, 6p
Autor:
Rejc, Luka, Gómez-Vallejo, Vanessa, Rios, Xabier, Cossío, Unai, Baz, Zuriñe, Mujica, Edurne, Gião, Tiago, Cotrina, Ellen Y., Jiménez-Barbero, Jesús, Quintana, Jordi, Arsequell, Gemma, Cardoso, Isabel, Llop, Jordi
Publikováno v:
Journal of Alzheimer's Disease; 2020, Vol. 77 Issue 1, p99-112, 14p
Publikováno v:
Journal of Neurochemistry; Jul2020, Vol. 154 Issue 1, p11-24, 14p
Autor:
Niloofar Bazazzadegan, Marzieh Dehghan Shasaltaneh, Kioomars Saliminejad, Koorosh Kamali, Mehdi Banan, Reza Nazari, Gholam Hossein Riazi, Hamid Reza Khorram Khorshid
Publikováno v:
Advanced Pharmaceutical Bulletin, Vol 7, Iss 4, Pp 629-636 (2017)
Purpose: Alzheimer’s disease (AD) is pathologically defined by the presence of amyloid plaques and tangles in the brain, therefore, any drug or compound with potential effect on lowering amyloid plaques, could be noticed for AD management especiall
Externí odkaz:
https://doaj.org/article/bc03bad2f71349d28d5f39a29ccc17f4
Autor:
Polissidis, Alexia1 (AUTHOR) apolissidis@bioacademy.gr, Petropoulou-Vathi, Lilian1 (AUTHOR), Nakos-Bimpos, Modestos1 (AUTHOR), Rideout, Hardy J.1 (AUTHOR) hrideout@bioacademy.gr
Publikováno v:
Biomolecules (2218-273X). Jun2020, Vol. 10 Issue 6, p912-912. 1p.
Publikováno v:
FEBS letters. 579(21)
beta-Amyloid peptide (Abeta) is the major constituent of senile plaques, the key pathological feature of Alzheimer's disease. Abeta is physiologically produced as a soluble form, but aggregation of Abeta monomers into oligomers/fibrils causes neuroto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cc3d8922a4008a9c2caf6d6614ac314
https://pubmed.ncbi.nlm.nih.gov/16098972
https://pubmed.ncbi.nlm.nih.gov/16098972